Medical Technology Industry: Main Revenue Source
Patient Monitoring Systems: 40%
Cardiological Products: 30%
Neurological Products: 20%

TOP 3 Markets:

1. Japan: 50%
2. USA: 25%
3. Europe: 15%

Nihon Kohden Corporation generates the majority of its revenue from the medical technology industry, particularly through patient monitoring systems, cardiological, and neurological products. The domestic market of Japan is the largest single market, followed by the USA and Europe, which also make significant contributions to the total revenue. The strong presence in Japan is attributed to the long-standing market leadership and trust in the quality of the products. In the USA and Europe, the company benefits from the increasing demand for advanced medical technologies.

Production Sites: Japan, USA, China

Nihon Kohden Corporation mainly produces its products in Japan, where the company's headquarters are also located. In addition, the company has production facilities in the USA and China to better serve the demand in international markets. This geographical diversification enables Nihon Kohden to respond more efficiently to regional market requirements and optimize supply chains.

Revenue Growth: 6.5% (2025) Research & Development: 8% of revenue (2025)

Nihon Kohden Corporation pursues a strategy that heavily focuses on innovation and technological development. A key component of this strategy is increasing investments in research and development, which accounted for approximately 8% of revenue in 2025. This demonstrates the company's commitment to expanding its product range and developing new technologies to remain competitive in the medical technology industry.

Furthermore, Nihon Kohden is concentrating on international expansion, particularly in emerging markets, to meet the demand for medical devices in those regions. These markets offer significant growth potential as the healthcare infrastructure in many of these countries is being developed.

Another strategic priority is enhancing operational efficiency. By optimizing production processes and cost savings, the company aims to improve its margins while ensuring the quality of its products.

Main raw materials: Electronic components, metals, plastics

Countries of origin: China, Japan, South Korea, Germany

Nihon Kohden Corporation is a leading manufacturer of medical devices and technologies. The company mainly imports electronic components that are essential for the production of medical devices. These components often come from China and South Korea, which are known for their electronics production.

Metals and plastics needed for the casings and other parts of the devices are sourced both locally in Japan and imported from Germany. Germany is renowned for its high-quality industrial materials and precision parts used in medical technology.

This import strategy enables Nihon Kohden to offer high-quality products at competitive prices by benefiting from the best available materials and technologies worldwide.

Market share in Japan: approximately 30% (2025)
Research & Development (R&D) expenses: 8.5% of revenue (2025)
Gross margin: 48% (2025)

Nihon Kohden Corporation has a significant competitive advantage, especially in the Japanese market, where the company holds a market share of about 30%. This is a sign of its strong market position and customers' trust in its products.

The company continuously invests in research and development, accounting for approximately 8.5% of its revenue. These investments enable Nihon Kohden to develop innovative medical devices and differentiate itself from the competition.

The 48% gross margin indicates that the company is able to offer its products at a premium price, reflecting a strong brand perception and product quality. These factors significantly contribute to its competitive advantage.

Institutional Investor Share: Estimated 45% (2026)

Insider Buys/Sells: No significant transactions in the last year

The institutional investor share in Nihon Kohden Corporation is approximately 45%. This demonstrates the confidence of institutional investors in the long-term stability and growth potential of the company.

Regarding insider transactions, there were no significant buys or sells in the last year, indicating a stable assessment of the company's value by management and other insiders. This can be seen as a positive signal for market participants, as it reflects confidence in the company's future development.

Market share of Nihon Kohden Corporation: Estimated 5-7% (2026)

Top competitors and their market shares:

1. Medtronic plc: 15-18%
2. Philips Healthcare: 10-12%
3. GE Healthcare: 8-10%
4. Siemens Healthineers: 7-9%
5. Fujifilm Holdings Corporation: 5-7%
6. Nihon Kohden Corporation: 5-7%
7. Boston Scientific Corporation: 4-6%
8. Johnson & Johnson: 4-6%
9. Canon Medical Systems Corporation: 3-5%
10. Hitachi Medical Corporation: 3-5%

Nihon Kohden Corporation is a significant player in the medical devices sector, particularly in monitoring and diagnostics. The company's market share is estimated at 5-7%, making it one of the leading companies in this sector.

Nihon Kohden's moat is based on its specialization and innovation in monitoring technology. The company has a strong presence in Asia and is continuously expanding into other markets.

Compared to larger competitors like Medtronic or Philips, which have a broader product portfolio and a stronger global presence, Nihon Kohden's moat is less pronounced. These companies benefit from larger research and development budgets and greater market penetration.

Overall, Nihon Kohden has a significant advantage in its niche, but larger competitors with more extensive resources and global networks may have a stronger moat.

Revenue Growth: 8.2% (2025) Profit Growth: 6.5% (2025) Research & Development Expenses: 10% of revenue (2025)

In 2025, Nihon Kohden Corporation recorded a revenue growth of 8.2%, indicating strong demand for their medical devices and solutions. The profit growth of 6.5% during the same period shows that the company is able to improve its profitability despite rising costs.

Another positive aspect is the investment in research and development, which accounts for 10% of revenue. This suggests that Nihon Kohden is committed to developing innovative products and strengthening its market position in the long term.

In summary, the financial performance and strategic direction of the company indicate that Nihon Kohden Corporation could be a solid investment, especially for investors interested in long-term growth.

Dividend Yield: 2.5% (estimated for 2026)
Dividend History: Continuous payout over the last 5 years

Nihon Kohden Corporation has pursued a stable dividend policy in recent years. The company is known for regularly distributing dividends to its shareholders. The estimated dividend yield for 2026 is around 2.5%, which is in line with previous payouts.

The reliability of dividend payments is supported by the company's solid financial performance. Nihon Kohden holds a strong market position in the medical technology sector and benefits from a stable demand for its products. This enables the company to pay dividends even in economically challenging times.